Form 4: Southpoint Capital Sells Fennec Pharma Shares

Southpoint Capital Advisors, a 10% owner and director, reported selling over 67,000 shares of Fennec Pharmaceuticals common stock in early October 2025.

Summary

• Southpoint Capital Advisors LP, along with its affiliated entities (Southpoint Capital Advisors LLC, Southpoint GP, LP, Southpoint GP, LLC) and John S. Clark II, reported sales of Fennec Pharmaceuticals Inc. (FENC) common stock.
• The reporting persons are identified as both a Director and a 10% Owner of Fennec Pharmaceuticals Inc.
• A total of 67,114 shares of common stock were sold across three separate transactions in October 2025.
• The sales occurred on October 7, 2025 (26,900 shares at a weighted average price of $9.5871), October 8, 2025 (19,605 shares at $9.4732), and October 9, 2025 (20,609 shares at $9.3461).
• Following these transactions, the beneficial ownership of the reporting persons decreased to 4,010,100 shares.
• The securities are indirectly held by Southpoint Master Fund, LP, for which Southpoint Capital Advisors LP serves as the investment manager.

Sentiment

Score: 3

Explanation: The filing indicates significant insider selling by a major shareholder and director, which is generally perceived as a negative signal for the stock's immediate future performance.

Negatives

• Significant insider selling by a 10% owner and director, Southpoint Capital Advisors LP and its affiliates, totaling 67,114 shares of Fennec Pharmaceuticals common stock.
• The sales occurred at declining weighted average prices, from $9.5871 on October 7, 2025, to $9.3461 on October 9, 2025.
• The transactions reduced the reporting persons' beneficial ownership from 4,077,214 shares (before the first reported sale) to 4,010,100 shares.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The filing clarifies the indirect beneficial ownership structure, stating that the securities are directly held by Southpoint Master Fund, LP, for which Southpoint Capital Advisors LP serves as the investment manager. Southpoint Capital Advisors LLC serves as the general partner of Southpoint Capital Advisors LP, and Southpoint GP, LP and Southpoint GP, LLC are also involved in the general partnership structure, with John S. Clark II serving as managing member of key entities. This details the chain of control and beneficial interest among the reporting persons.

Stakeholder Impact

• Shareholders may interpret the significant insider selling by a 10% owner and director as a negative signal regarding the company's future prospects or current valuation, potentially leading to decreased investor confidence.

Key Dates

Recommendation

The consistent selling by a 10% owner and director, Southpoint Capital Advisors, suggests that a key insider with deep knowledge of the company's operations and prospects is reducing their exposure. This action, particularly over multiple days and at slightly declining prices, could indicate a belief that the stock is fully valued or that negative developments may be on the horizon. For a seasoned investor, this insider selling activity warrants a cautious approach, potentially leading to a 'sell' recommendation to mitigate risk or reallocate capital.

Keywords

Fennec Pharmaceuticals, FENC, Southpoint Capital Advisors, Insider Selling, Form 4, Beneficial Ownership, Stock Sale, Director Transaction, 10% Owner